| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PNAS..108.1439L |
| P356 | DOI | 10.1073/PNAS.1012500108 |
| P932 | PMC publication ID | 3029686 |
| P698 | PubMed publication ID | 21220347 |
| P5875 | ResearchGate publication ID | 49741945 |
| P50 | author | Andrew B. West | Q37378096 |
| Thomas Giordano | Q37621567 | ||
| Bin Tean Teh | Q47451223 | ||
| Jeffrey P MacKeigan | Q57321283 | ||
| Brendan D Looyenga | Q64513884 | ||
| P2093 | author name string | Karl J Dykema | |
| Kyle A Furge | |||
| James H Resau | |||
| Pamela J Swiatek | |||
| Julie Koeman | |||
| P2860 | cites work | Bioconductor: open software development for computational biology and bioinformatics | Q21194861 |
| Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data | Q24537656 | ||
| Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma | Q24806069 | ||
| Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 | ||
| The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit | Q72560868 | ||
| Characterization of a new animal model for human renal cell carcinoma | Q74031617 | ||
| Genomic imbalances in 61 renal cancers from the proximal tubulus detected by comparative genomic hybridization | Q74440655 | ||
| Significance of trisomy 7 and 12 in thyroid lesions with follicular differentiation: a cytogenetic and in situ hybridization study | Q77352909 | ||
| Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas | Q81040981 | ||
| Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC | Q81746525 | ||
| Classification of renal neoplasms based on molecular signatures | Q83335203 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Autophagic cell death: the story of a misnomer | Q29614564 | ||
| Critical nodes in signalling pathways: insights into insulin action | Q29614735 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma | Q31108141 | ||
| How aneuploidy may cause cancer and genetic instability | Q33851935 | ||
| LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease | Q34299954 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population | Q34364668 | ||
| A molecular classification of papillary renal cell carcinoma | Q34558981 | ||
| Identification of genes differentially expressed in benign versus malignant thyroid tumors | Q34913566 | ||
| Detection of numerical alterations for chromosomes 7 and 12 in benign thyroid lesions by in situ hybridization. Histological implications | Q35796348 | ||
| Cancer therapy: can the challenge be MET? | Q36159458 | ||
| Activating mutations for the met tyrosine kinase receptor in human cancer | Q36595980 | ||
| Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. | Q36860354 | ||
| Met and hepatocyte growth factor/scatter factor expression in human gliomas | Q36894692 | ||
| Aberrant receptor signaling and trafficking as mechanisms in oncogenesis | Q36979383 | ||
| Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors | Q37539304 | ||
| Biological significance of c-met over expression in papillary renal cell carcinoma | Q38456509 | ||
| Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene | Q38497635 | ||
| Endosomal dynamics of Met determine signaling output | Q39745537 | ||
| Growth factor independence and growth regulatory pathways in human melanoma development | Q40801225 | ||
| HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney | Q41499933 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors | Q56976288 | ||
| Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis | Q58053853 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1439-1444 | |
| P577 | publication date | 2011-01-10 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas | |
| P478 | volume | 108 |
| Q47137783 | Biological and Clinical Implications of Comorbidities in Parkinson's Disease |
| Q38433725 | Cellular processes associated with LRRK2 function and dysfunction |
| Q28073283 | Choosing the right cell line for renal cell cancer research |
| Q26745344 | Chronic Inflammation Links Cancer and Parkinson's Disease |
| Q39206423 | Clinical Features of LRRK2 Carriers with Parkinson's Disease |
| Q40283731 | Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines |
| Q35042618 | Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid |
| Q38985873 | Cutaneous malignant melanoma and Parkinson disease: Common pathways? |
| Q41849532 | Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. |
| Q92628733 | Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway |
| Q90641550 | Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities |
| Q92566144 | Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model |
| Q55014055 | Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease. |
| Q64056093 | Factor Analysis for Bicluster Acquisition (FABIA) revealed vincristine-sensitive transcript pattern of canine transmissible venereal tumors |
| Q38363786 | Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond |
| Q36241043 | Functional significance of CD105-positive cells in papillary renal cell carcinoma. |
| Q47071359 | Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival |
| Q27303568 | High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain |
| Q35195815 | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis |
| Q90496377 | Identification of hub driving genes and regulators of lung adenocarcinoma based on the gene Co-expression network |
| Q39432024 | Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin. |
| Q38430213 | Integrated analysis of differential expression and alternative splicing of non-small cell lung cancer based on RNA sequencing |
| Q38869514 | LRRK2 and Autophagy |
| Q38044446 | LRRK2 and autophagy: a common pathway for disease. |
| Q44103469 | LRRK2 and human disease: a complicated question or a question of complexes? |
| Q38253871 | LRRK2 pathobiology in Parkinson's disease |
| Q35288337 | LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice |
| Q36073860 | Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression |
| Q31144492 | Measuring intratumor heterogeneity by network entropy using RNA-seq data |
| Q38132039 | Molecular targets on the horizon for kidney and urothelial cancer |
| Q36182819 | Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? |
| Q40200165 | Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma |
| Q37948585 | Parkinson's disease and cancer: two wars, one front |
| Q42263195 | Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. |
| Q37346559 | Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET. |
| Q55263191 | Recalling Cohnheim's Theory: Papillary Renal Cell Tumor as a Model of Tumorigenesis from Impaired Embryonal Differentiation to Malignant Tumors in Adults. |
| Q38005625 | Renal cell carcinoma deep sequencing: recent developments |
| Q58778664 | SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition Wnt/β-Catenin Pathway |
| Q28482925 | Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation |
| Q99709324 | TM4SF4 and LRRK2 are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis |
| Q27007413 | Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic |
| Q26778641 | The associations between Parkinson's disease and cancer: the plot thickens |
| Q46633577 | The common PARK8 mutation LRRK2G²⁰¹⁹S is not a risk factor for breast cancer in the absence of Parkinson's disease |
Search more.